Show simple item record

dc.contributor.authorZeidan, AM
dc.contributor.authorBoss, IW
dc.contributor.authorBeach, CL
dc.contributor.authorCopeland, WB
dc.contributor.authorThompson, EG
dc.contributor.authorFox, BA
dc.contributor.authorHasle, VE
dc.contributor.authorHellmann, A
dc.contributor.authorTaussig, D
dc.contributor.authorTormo, M
dc.contributor.authorVoso, MT
dc.contributor.authorCavenagh, J
dc.contributor.authorO'Connor, T
dc.contributor.authorPrevitali, A
dc.contributor.authorRose, S
dc.contributor.authorSilverman, LR
dc.date.accessioned2022-05-09T14:46:20Z
dc.date.available2022-05-09T14:46:20Z
dc.date.issued2021-12-21
dc.identifier.citationBlood advances, 2021en
dc.identifier.issn2473-9529
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5115
dc.identifier.eissn2473-9537en_US
dc.identifier.eissn2473-9537
dc.identifier.doi10.1182/bloodadvances.2021006138en_US
dc.identifier.doi10.1182/bloodadvances.2021006138
dc.description.abstractEvidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death ligand 1 (PD-L1) inhibitor, combined with azacitidine for patients aged ≥65 years with acute myeloid leukemia (AML), including analyses to identify biomarkers of treatment response. Patients were randomized to first-line therapy with azacitidine 75 mg/m2 on days 1-7 with (Arm A, n= 64) or without (Arm B, n=65) durvalumab 1500 mg on day 1 every 4 weeks. Overall response rate (complete response [CR] + CR with incomplete blood recovery [CRi]) was similar in both arms (Arm A, 31.3%; Arm B, 35.4%), as were overall survival (A, 13.0 months; B, 14.4 months) and duration of response (A, 24.6 weeks; B, 51.7 weeks; P=0.0765). No new safety signals emerged with combination treatment. The most frequently reported treatment-emergent adverse events were constipation (Arm A, 57.8%; Arm B, 53.2%) and thrombocytopenia (A, 42.2%; B, 45.2%). DNA methylation, mutational status, and PD-L1 expression were not associated with response to treatment. In this study, first-line combination therapy with durvalumab and azacitidine in older patients with AML was feasible, but did not improve clinical efficacy compared with azacitidine alone. ClinicalTrials.gov: NCT02775903.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden
dc.titleAzacitidine and Durvalumab in First-line Treatment of Elderly Patients With Acute Myeloid Leukemia.en
dc.typeJournal Article
dcterms.dateAccepted2021-11-24
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.1182/bloodadvances.2021006138en
rioxxterms.licenseref.startdate2021-12-21
dc.relation.isPartOfBlood advancesen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia/Acute Leukaemia (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.embargo.termsNot knownen_US
icr.researchteamAcute Leukaemia
dc.contributor.icrauthorTaussig, Daviden_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record